Clinical Trials Browser

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Penile Squamous Cell Carcinoma (PSCC)

Muscle-invasive Bladder Cancer

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Metastatic Urothelial Cancer

Carcinoma, Transitional Cell

Advanced Bladder Cancer

Muscle Invasive Bladder Urothelial Carcinoma

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

Metastatic Castration-resistant Prostate Cancer

Urinary Bladder Neoplasms, Ureteral Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

Renal Pelvis and Ureter Urothelial Carcinoma

Carcinoma, Transitional Cell, Neoplasm Metastasis

Clinical Trials

FORAGER-1

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

VOLGA

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

MK-3475-04D

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

EV-103

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

TROPHY U-01

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

IMPROEV

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

MK-3475-04C

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

SOGUG-PRINCIS

ENCORE

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

KEYNOTE-B15

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Circulating Tumor DNA Response In Urothelial Cancer